Latest news with #biodefense
Associated Press
30-06-2025
- Business
- Associated Press
Renovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security Needs
LOS ANGELES, CALIFORNIA / ACCESS Newswire / June 30, 2025 / Renovaro Inc.'s (NASDAQ:RENB) wholly owned subsidiary BioSymetrics has unveiled a proprietary AI-based zebrafish screening platform designed to rapidly identify medical countermeasures for neurotoxic chemical agents, including weaponized substances like Sarin. The platform has been integrated into Renovaro's Defense Countermeasures Program, marking a strategic entry into the dual-use biotechnology and biodefense sector. Renovaro's platform is anchored by advanced data preprocessing coupled with in vivo toxicity testing, creating a robust, end-to-end discovery pipeline bolstered by their recently announced patent, 'Methods, Systems, and Frameworks for Unbiased Data in Drug Discovery Predictions'. This IP milestone expands the company's foundational portfolio, further protecting its machine learning infrastructure for multi-modal biomedical data integration and predictive analytics-core to its scalable drug discovery and diagnostics business. 'This is a defining moment for Renovaro as we extend the value of our AI platform from traditional life sciences into national security,' said David Weinstein, CEO of Renovaro. 'With a growing patent estate and entry into the defense market, we are unlocking new revenue channels and expanding the commercial potential of our core technologies.' Value Drivers: The AI-based platform which uses an inexpensive zebrafish-based model for validation of neurotoxicity predictions, delivers rapid, automated screening of over 1,000 compounds per week, significantly outpacing traditional animal models. It captures behavioural, cardiovascular, and muscular responses to neuroactive chemicals, enabling ML-driven compound triage and mechanism of action prediction. This capability is vital for both commercial CNS drug discovery and defense applications involving neurotoxic exposure. 'Investors increasingly seek companies with platforms that are both scientifically robust and commercially scalable,' said Weinstein. 'Our ability to serve large markets in biopharma and national security - each with deep funding pools and urgent unmet needs - creates a unique, de-risked growth trajectory.' About Renovaro Inc. Renovaro Inc. (NASDAQ: RENB) is building category-defining AI-driven platforms for precision medicine, diagnostics, and biodefense. Its proprietary technologies transform complex biomedical data into predictive insights, enabling faster discovery, greater accuracy, and strategic partnerships across the life sciences and government sectors. Investor Relations Contact: Your Name: Nathen Fuentes Title CFO [email protected] Company Website: SOURCE: Renovaro Biosciences press release
Yahoo
23-06-2025
- Science
- Yahoo
OpenAI Concerned That Its AI Is About to Start Spitting Out Novel Bioweapons
OpenAI is bragging that its forthcoming models are so advanced, they may be capable of building brand-new bioweapons. In a recent blog post, the company said that even as it builds more and more advanced models that will have "positive use cases like biomedical research and biodefense," it feels a duty to walk the tightrope between "enabling scientific advancement while maintaining the barrier to harmful information." That "harmful information" includes, apparently, the ability to "assist highly skilled actors in creating bioweapons." "Physical access to labs and sensitive materials remains a barrier," the post reads — but "those barriers are not absolute." In a statement to Axios, OpenAI safety head Johannes Heidecke clarified that although the company does not necessarily think its forthcoming AIs will be able to manufacture bioweapons on their own, they will be advanced enough to help amateurs do so. "We're not yet in the world where there's like novel, completely unknown creation of biothreats that have not existed before," Heidecke said. "We are more worried about replicating things that experts already are very familiar with." The OpenAI safety czar also admitted that while the company's models aren't quite there yet, it expects "some of the successors of our o3 (reasoning model) to hit that level." "Our approach is focused on prevention," the blog post reads. "We don't think it's acceptable to wait and see whether a bio threat event occurs before deciding on a sufficient level of safeguards." As Axios notes, there's some concern that the very same models that assist in biomedical breakthroughs may also be exploited by bad actors . To "prevent harm from materializing," as Heidecke put it, these forthcoming models need to be programmed to "near perfection" to both recognize and alert human monitors to any dangers. "This is not something where like 99 percent or even one in 100,000 performance is sufficient," he said. Instead of heading off such dangerous capabilities at the pass, though, OpenAI seems to be doubling down on building these advanced models, albeit with ample safeguards. It's a noble enough effort, but it's easy to see how it could go all wrong. Placed in the hands of, say, an insurgent agency like the United States' Immigrations and Customs Enforcement, it would be easy enough to use such models for harm. If OpenAI is serious about so-called "biodefense" contracting with the US government, it's not hard to envision a next-generation smallpox blanket scenario. More on OpenAI: Conspiracy Theorists Are Creating Special AIs to Agree With Their Bizarre Delusions
Yahoo
19-06-2025
- Business
- Yahoo
Biodefense Market Size worth $22.8 billion, Globally, by 2030 with 5% CAGR - Exclusive Study by The Research Insights
CHICAGO, June 19, 2025 /PRNewswire/ -- The global biodefense market size is projected to be valued at USD 16.1 billion in 2023 and reach USD 22.8 billion by 2030, growing at a CAGR of 5.0% according to a new report by The Research Insights. The biodefense market has experienced significant expansion recently due to the rising critical threat posed by emerging infectious diseases. The rapid impact of pandemics such as COVID-19, Ebola, and Monkeypox has shown how diseases can quickly cause healthcare system failures and lead to economic and social disruptions. Current health crises prove the necessity of having strong preparedness and resilience systems to manage biological hazards from natural occurrences and human-made threats. Global governments and health organizations have increased their biodefense system efforts in response to recent events. The report runs an in-depth analysis of market trends, key players, and future opportunities. In general, the biodefense market growth of 5.0% comprises product, application, end use and geography which are expected to register strength during the coming years. For More Information and To Stay Updated on The Latest Developments in The Biodefense Market Share, Download FREE Sample Pages: Market Overview and Growth Trajectory: Biodefense Market Growth: According to an exhaustive report by The Research Insights, the Biodefense Market is undergoing significant growth, driven by the rising focus on dual-use technologies which provide benefits for both military and national security applications as well as public health initiatives. The COVID-19 pandemic highlighted that technologies designed for biodefense purposes can be adapted rapidly for pandemic preparedness and the reverse is also true. The biodefense market is increasingly recognizing that investing in technologies with dual applications creates a win-win scenario: National administrations expand their biodefense strength at the same time they boost public health resilience. Next-Gen Science Fortifies Global Shields Against Biological Threats: As global health and security rapidly change today, biodefense market capabilities are being transformed by technological advancements. Technological advances in synthetic biology and genomic surveillance along with rapid diagnostics and vaccine development platforms now provide nations with advanced capabilities to quickly identify, stop, and address biological threats precisely. Using synthetic biology scientists can quickly modify microorganisms to create specific vaccines and treatments after identifying new pathogens. The swift creation of mRNA vaccines during the COVID-19 pandemic established a new standard for rapid vaccine development. Current technological advances offer improved preparedness for both upcoming pandemics and bioterror attacks. The practice of genomic surveillance stands as a pivotal development because its capabilities allow scientists to detect unusual microbial activity or new pathogens early on. The integration of AI-powered analytics with this capability allows for the prediction of outbreaks before they worsen which enables governments to take early action rather than waiting to respond. These technologies go beyond simple technical enhancements to illustrate a fundamental change in approach. The biodefense industry is transitioning from outdated reactive approaches to advanced tech-driven ecosystems that respond instantly to changes. The world is developing smarter security systems through innovation to protect against biological attacks and maintain public health in today's complex and unpredictable global environment. For Detailed Market Insights, Visit: Bioterrorism Fears Ignite Urgent Global Race for Biodefense Preparedness: As warfare boundaries blur between traditional methods and unconventional dangers, bioterrorism emerges as a primary global threat. The threat of terrorist organizations creating weapons from deadly pathogens either found in nature or created in labs has become a more credible danger which motivates governments globally to respond rapidly and forcefully. Increased awareness about bioterrorism threats is leading to fast expansion in the biodefense market as countries work urgently to strengthen their public health systems and national security defenses. The accessibility of CRISPR and synthetic biology tools has transformed intentional outbreak risks into real national security threats. Governments are increasing their spending on early-warning systems and biosurveillance networks while building emergency vaccine and treatment stockpiles to combat biological threats. The biodefense market sees increasing R&D efforts towards developing rapid-response platforms designed to swiftly detect and tackle new pathogens. Defense departments and biotech companies along with public health agencies are building more alliances to maintain an advantage over possible threats. Global Governments Step Up as First Responders in the Biodefense Race: Governments worldwide have become the primary support system for the biodefense market due to increasing biological threats including pandemics and potential bioterrorist attacks. Public sector agencies allocate substantial resources toward preparedness and research infrastructure because they understand that delayed responses to biological threats lead to uncontrollable crises. The U.S. Department of Defense (DoD) and the Biomedical Advanced Research and Development Authority (BARDA) have demonstrated strong commitment by investing billions of dollars in vaccine research and development along with rapid diagnostic tools and advanced digital therapeutics. Public-private partnerships that support biodefense readiness today have emerged alongside accelerated innovation through these targeted investments. The strategic investment in funding extends beyond emergency situations. Long-term research and development programs targeting emerging threats and dual-use technologies now receive expanded government support together with manufacturing resilience efforts. The biodefense market evolves into a dynamic and forward-looking domain through collaboration because stakeholders recognize that health security requires shared global responsibilities and starts with policy and public funding. Stay Updated on The Latest Biodefense Market Trends: Geographical Insights: The biodefense market is dominated by North America with the United States accounting for most of its share. Federal financial support combined with established programs and sophisticated biotechnology facilities drive regional advantages. The Department of Defense (DoD), Biomedical Advanced Research and Development Authority (BARDA), and Department of Homeland Security (DHS) prioritize biodefense within their national security strategies. The biodefense market in Europe continues to expand due to transnational health security programs and insights obtained from the COVID-19 pandemic. The European Union created the Health Emergency Preparedness and Response Authority (HERA) to manage biodefense tasks while supporting research development and maintaining a reserve of countermeasures. National laboratories along with disease surveillance systems and vaccine manufacturing facilities receive investments from Germany, France and the UK. The biodefense market in the Asia Pacific region is undergoing swift growth particularly in nations including China and Japan as well as South Korea and India. The outbreak of diseases such as SARS and H1N1 followed by COVID-19 drove important investments in biodefense measures. Biodefense Market Segmentation and Geographical Insights: Based on product, the biodefense market is divided into anthrax, smallpox, botulism, radiation/nuclear and others. The anthrax segment held the largest share of the biodefense market in 2024. Based on application, the biodefense market is divided into biological threat detection, medical countermeasures and decontamination. The medical countermeasures segment held the largest share of the biodefense market in 2024. Based on end use, the biodefense market is divided into government, military, healthcare and research institutions. The government segment accounted for a larger share of the biodefense market in 2024. The biodefense market is segmented into five major regions: North America; Europe; Asia Pacific; Latin America; Middle East & Africa. Purchase Premium Copy of Global Biodefense Market Size and Growth Report (2023-2030) at: Key Players and Competitive Landscape: The Biodefense Market is characterized by the presence of several major players, including: XOMA corporation Altimmune Inc. Emergent Biosolutions Inc. Dynavax Technologies Corporation. SIGA Technologies. Elusys Therapeutics Inc. Ichor Medical Systems. Dynport Vaccine Company. Cleveland Biolabs. Bavarian Nordic. Ology Bioservices. Alnylam Pharmaceuticals Inc These companies are adopting strategies such as new product launches, joint ventures, and geographical expansion to maintain their competitive edge in the market. Biodefense Market Recent Developments and Innovations: In February 2025, Thermo Fisher Scientific (US) announced the acquisition of the Solventum (US) Purification and Filtration business for USD 1.5 billion in cash. This strategic acquisition will expand Thermo Fisher's bioproduction capabilities, particularly in filtration technologies essential for biologics manufacturing. In September 2024, Synexis (US) announced a strategic partnership with Diversey(US), a global leader in hygiene and infection prevention solutions, to expand the reach of its Dry Hydrogen Peroxide (DHP™) technology. In March 2024, Emergent BioSolutions Inc. (EBS), received United States Food and Drug Administration (FDA) approval for BioThrax, for pre-exposure prophylaxis and post-exposure prophylaxis of anthrax disease. For Region-Specific Market Data, Check Out Brief Sample Pages: Key Questions Addressed: 1. What is the key opportunity in the biodefense market?- Collaboration between government agencies and pharmaceutical/biotech companies offers scalable and responsive biodefense strategies. 2. What is the expected market size for biodefense market by 2030? - The expected market size for biodefense is USD 22.8 Billion in 2030. 3. Which are the major end use where biodefense is used?- Major end use includes government, military, healthcare and research institutions. 4. Which product segment for biodefense market has the potential to register the highest market share? - Anthrax segment for biodefense market is expected to register highest market share of 31% in 2024. 5. Which region is estimated to witness a high demand for biodefense over the forecast period? - Asia Pacific is estimated to witness a high demand for biodefense growing at a CAGR of 9.1% over the forecast period 6. Who are the key players in biodefense market?- The key players in the market are XOMA corporation, Altimmune Inc., Emergent Biosolutions Inc., Dynavax Technologies Corporation., SIGA Technologies., Elusys Therapeutics Inc., Ichor Medical Systems., Dynport Vaccine Company., Cleveland Biolabs., Bavarian Nordic., Ology Bioservices and Alnylam Pharmaceuticals Inc. Conclusion: The biodefense market experiences rapid global expansion because of rising bioterrorism threats alongside emerging infectious diseases and growing awareness of health security at national and global levels. The worldwide market landscape is evolving to adopt proactive technological approaches which include advancements in mRNA vaccine platforms, genomic surveillance technologies, synthetic biology, and AI-based biosurveillance systems to boost biodefense readiness. Dual-use technology advancements help connect pandemic response with national security efforts thus establishing biodefense as the cornerstone of modern public health systems. Despite ongoing obstacles like regulatory challenges and substantial development expenses combined with ethical concerns the need for globally coordinated and balanced solutions remains essential. The biodefense market will keep developing as a crucial multidisciplinary ecosystem spurred by innovation through international cooperation and steadfast government support due to increasing complexity in biological threats. Need A Diverse Region or Sector? Customize Research to Suit Your Requirement: The report from The Research Insights, therefore, provides several stakeholders—including raw material & technology providers, product developers & biotech manufacturers, government regulators, system integrators and end users —with valuable insights into how to successfully navigate this evolving market landscape and unlock new opportunities. With projected growth to US$ 22.8 billion by 2030, the Biodefense Market represents a significant opportunity for raw material & technology providers, product developers & biotech manufacturers, government regulators, system integrators, end-users, investors, industry stakeholders, and others. By staying abreast of market trends, embracing innovation, and focusing on quality and performance, companies can position themselves for success in this dynamic and evolving market landscape. Check out more related studies published by The Research Insights: mRNA Therapeutics Market - The global mRNA therapeutics market size is expected to reach USD 31.30 billion by 2030, according to a new report by The Research Insights. It is projected to register a CAGR of 17.05% during the forecast period, driven primarily by remarkable potential of mRNA-based therapeutics in addressing chronic diseases. Bio Decontamination Market - The global bio decontamination market size is expected to reach USD 396.49 million by 2030, according to a new report by The Research Insights. It is projected to expand at a CAGR of 8.62% from 2024 to 2030. This projected expansion can be attributed to several key factors, including the increasing number of surgical procedures, which heightens the risk of hospital-acquired infections (HAIs). Predictive Disease Analytics Market - The global predictive disease analytics market size is anticipated to reach USD 10.2 billion by 2030 and is projected to grow at a CAGR of 22.7% from 2023 to 2030, according to a new report by The Research Insights. The market is expected to experience substantial growth in the coming years, driven by its transformative potential in improving patient outcomes and streamlining healthcare delivery. Browse More related reports on Healthcare Market – About The Research Insights: The Research Insights provides thoroughly conducted research which is backed up by real-time statistics and data. Our experts are eager to help you with any information required under the sun. The key to our success is keeping abreast with the markets, industries, and ever-changing consumer trends that matter. Our market research professionals have in-depth knowledge and expertise across various domains that includes IT and Telecom, Emerging Technologies, Consumer Offerings, Manufacturing and Others. We are committed to reviewing the scope and procedure of the research studies that you select and provide you with an accurate guidance in order to assist you in taking the correct business decisions. Contact Us:If you have any queries about this report or if you would like further information, please contact us:Contact Person: Kaushik RoyE-mail: sales@ +1-312-313-8080Blog: Press Release: Latest News: | Logo - View original content: SOURCE The Research Insights
Yahoo
19-06-2025
- Health
- Yahoo
e4life Devices Take Stage at Japan Health in Osaka from 25th to 27th June
Can electromagnetic waves neutralize respiratory viruses? Now they can! This technology, developed by the Italian company e4life, has an efficacy rate of over 90% - confirmed by several research laboratories - neutralising influenza, RSV and Covid viruses, and it is capable of protecting both humans and animals against respiratory viruses In addition, a recent study published in Nature Scientific Reports demonstrates e4life effectiveness against the Avian Flu virus. Vincenzo Pompa, e4life CEO: "The One Health aims to reduce the risk of spillover between animals and humans and to allow each individual to enjoy a natural social life in safe spaces" ROME, June 19, 2025--(BUSINESS WIRE)--Can electromagnetic waves neutralize respiratory viruses? The answer is yes: on the stage of the Japan Health fair, from 25th to 27th June, e4life, the Italian company active in the biodefense industry, will be among the leading players presenting its innovative devices which use electromagnetic waves to render harmless respiratory viruses present in the air (transported via bioaerosol). This solution is a world first, with efficacy of over 90% and an almost instantaneous sanitizing action. Since it is 100% harmless to humans and animals, it does not require the evacuation of spaces and environments. This Italian patent does not use chemical agents or filter materials, and is based on the transmission of microwaves which, at a specific combination of frequency and power, act on the balance between the internal positive charges of the virus and the negative charges present in the capsid or outer shell, giving rise to a "resonance" phenomenon that destroys the external envelope of the virus and effectively inhibits its power to spread and to infect. The key intuitive moment came during the pandemic period and required two years of studies and in-depth analysis, starting from a research carried out by Taiwanese scientists published in the Nature Scientific Report. The first results came from testing different frequencies of electromagnetic waves on Covid and later, on other pathogens. One of the most interesting features of this new technology is the possibility of having a targeted action, allowing it to be calibrated on specific pathogens changing the resonance frequence. Its effectiveness has been validated against Covid, including recent variants, RSV and seasonal flu (in this case the effectiveness exceeds 95%), Avian Flu and Swine Flu. e4life has an important roadmap of research focused on constantly evolving and adapting the devices to an ever-increasing number of viruses and, in the near future, also bacteria. There are currently three products available using this technology, two for humans and one for animals. e4life personal is the portable, lightweight, compact version (100 grams x 8.5 cm) which is SAR certified. It is comfortable and safe to wear and is able to inactivate viruses by generating a "bubble" with a diameter of about three metres. Then there is e4life ambient which is the "fixed" version to be installed either on ceiling or walls with a range of action covering about 50 square metres. Lastly there is e4life FARM, the device dedicated to livestock farms and designed to combat animal viral diseases (actually Avian Flu and Swine Flu) which represent a threat to chicken, turkey and pigs. "This technology marks a breakthrough for applications in high-risk environments, both human and animal, such as farms, where controlling airborne virus transmission is essential, to minimize contagion among the animals themselves and also to reduce the risk of spillover - declares e4life CEO Vincenzo Pompa -. The focus and efficacy of our devices perfectly represent the meaning of what we are doing: it is the starting point of our commitment and it is closely linked to the concept of "One Health", an approach that recognizes and promotes the fundamental interconnection between human, animal and environmental health. Our goal is to revolutionize the biodefense sector through our solutions which allow each individual to enjoy a natural social life, interacting in safe spaces with no concerns or worries". Further confirmation of the value and importance of the results achieved by e4life are the numerous examples of recognition it has now received. In actual fact this technology has been subjected to scientific tests and has been validated by the Celio Military Hospital, the independent ViroStatics Institute and two studies published in the Viruses and the European Society of Medicine journals (Source: The technology has also been the subject of a test campaign carried out at Milan University's Department of Biomedical and Clinical Sciences. The results confirm those already obtained from previous test campaigns, i.e. a replicable efficacy of close to 90%. The Bio-Medico Campus at the University of Rome has instead collaborated in working on the control and efficacy of this technology. Furthermore, the JRC–HERA technological prospective study by the European Commission Joint Research Centre includes this technology among those which are currently available that can guarantee an increase in air quality in indoor environments. The already considerable number of validations has been expanded to include certification obtained from the University of Genoa, which has tested the technology's efficacy of over 90% on influenza and Covid viruses. A final further "seal of guarantee" comes from an article in the scientific journal Nature Scientific Reports, which describes a study demonstrating the effectiveness of electromagnetic waves in inactivating the avian flu virus. Moreover, the inactivation systems for respiratory viruses using electromagnetic waves have been included in the UNI/PdR 173-1 Reference Practices for Indoor Sanitization, a document drafted by UNI — the Italian Standardization Body — in collaboration with the National Institute of Health (Istituto Superiore di Sanità). This document sets out the requirements for managing indoor sanitization and the solutions that, even though they are not classified as medical devices, may be used for that purpose. The e4life devices are currently certified to be marketed in Europe, Australia, Japan, Singapore, Saudi Arabia, UAE, Morocco and Egypt. View source version on Contacts E4life press office Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
